Document and Entity Information Statement [Table] Statement [Line Items] Statement Common Stock Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Carrying amount as of the balance sheet date of research and development incentive receivable within one year or the operating cycle, if shorter. Research and Development Incentive Receivable, Current Research and development incentive receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Carrying amount as of the balance sheet date of research and development incentive receivable after one year from the balance sheet date (or one operating cycle, if longer) Research and Development Incentive Receivable, Noncurrent Research and development incentive receivable, net of current portion Deferred Tax Assets, Net, Noncurrent Deferred tax asset Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non Current liabilities: Warrants and Rights Outstanding Warrant liability Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 10) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.001 par value; 100,000,000 shares authorized; 14,500,681 and 12,354,014 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end of the period Balance at the beginning of the period Total stockholders' equity Liabilities and Equity Total liabilities, convertible preferred stock and stockholders' equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, authorized shares Common stock, shares authorized Common Stock, Shares, Issued Common stock, issued shares Common Stock, Shares, Outstanding Common stock, outstanding shares CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Investment Income Interest Expense Interest income Interest Expense Interest expense Interest Expense, Related Party Interest expense - related party Interest expense-related party Amount of income related to Australian research and development incentives recognized in the income statement. Research And Development Incentive Income Australian research and development incentives Australian research and development incentive income Foreign Currency Transaction Gain (Loss), before Tax Foreign currency gains (loss) Fair Value Adjustment of Warrants Loss on change in fair value of warrant liability Change in fair value of warrant liability Loss from change in fair value of warrant liability Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Temporary Equity, Accretion to Redemption Value, Adjustment Accretion of preferred stock to redemption value Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common stockholders Earnings Per Share, Basic and Diluted Net loss per share - basic and diluted (in dollars per share) Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding - basic and diluted (in shares) Weighted average number of common shares outstanding - basic and diluted (in shares) CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustments Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid In Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Loss Retained Earnings [Member] Retained Earnings Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Represents the information pertaining to subscription agreement which is a promise by the company to sell a given number of shares to an investor at a certain price, and an agreement by the investor to pay that price. Subscription Agreement [Member] Subscription Agreement Private Placement [Member] Private placement A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Increase (Decrease) in Shares Outstanding [Roll Forward] Increase (Decrease) in Shares Outstanding Shares, Outstanding Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Stock Issued During Period Shares New Issues Issuance of stock (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Increase in Carrying Amount of Redeemable Preferred Stock Accretion to redemption value Accretion of preferred stock to redemption value Debt Conversion, Converted Instrument, Amount Conversion of notes payable - related party and accrued interest into common stock Stock Issued During Period, Value, New Issues Purchase price Issuance of common stock, net of issuance costs Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Stock Transactions, Parenthetical Disclosures [Abstract] CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs associated with common stock Issuance of common stock, issuance costs CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation expense Share-based Compensation Stock-based compensation expense Amount of noncash interest expenses on related party. Noncash Interest Expense, Related Party Non-cash interest expense - related party Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, net of impact of assumed net assets of Macrocure: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets The increase (decrease) during the reporting period in amount due within one year (or one business cycle) with respect to research and development incentive receivable. Increase (Decrease) in Research and Development, Incentive Receivable Research and development incentive receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Amount of cash inflow from the issuance of common stock as consideration in a merger accounted for as an in-substance recapitalization. Proceeds from Issuance of Common Stock in Merger Accounted for as Recapitalization Proceeds from issuance of common stock in connection with merger with Macrocure Proceeds from Issuance of Common Stock Proceeds from issuance of common stock in connection with Subscription Agreement Proceeds from the issuance of common stock Amount of cash inflow from the issuance of common stock, net of underwriter commissions and discounts. Proceeds From The Issuance Of Common Stock, Net Of Underwriter Commissions And Discounts Proceeds from the issuance of common stock, net of underwriter commissions and discounts Proceeds from Related Party Debt Proceeds from notes payable - related party Proceeds from promissory notes Payments of Stock Issuance Costs Payment of deferred offering costs Issuance costs associated with private placement Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash financing activities: The amount of offering costs included in accounts payable and accrued expenses. Offering Costs Included in Accounts Payable and Accrued Expenses Offering costs included in accounts payable and accrued expenses Conversion of Stock, Amount Converted Conversion of convertible preferred stock into common stock Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Value of net assets acquired in connection with merger with Macrocure, excluding cash Nature of Business, Basis of Presentation and Liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Business, Basis of Presentation and Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Merger with Macrocure and Related Transactions Business Combination Disclosure [Text Block] Merger with Macrocure and Related Transactions Accrued Expenses The entire disclosure for accrued expenses. Accrued Expenses, Disclosure [Text Block] Accrued Expenses No definition available. Notes Payable-Related Party Represents the entire disclosure for information about all notes payable to related parties. Notes Payable Related Party [Text Block] Notes Payable-Related Party Warrants The entire disclosure of warrants. Warrants Disclosure [Text Block] Warrants Common Stock Stockholders' Equity Note Disclosure [Text Block] Common Stock Equity Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Equity Incentive Plans Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for research and development incentive income and receivables. Research And Development Incentive Income And Receivable [Policy Text Block] Research and development incentive income and receivable Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Disclosure of accounting policy for costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. Deferred Offering Costs [Policy Text Block] Deferred Offering Costs Disclosure of accounting policy for assets classified as other. Other Assets [Policy Text Block] Other Assets Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Disclosure of accounting policy for its warrant liability. Warrant Liability [Policy Text Block] Warrant Liability New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Tabular disclosure of the change in research and development incentive receivable. Schedule Of Change In Research And Development Incentive Receivable [Table Text Block] Schedule of change in the research and development incentive receivable Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of assets and liabilities carried at fair value in accordance with the hierarchy Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of the recurring fair value measurements of the warrant derivative liability categorized with Level 3 inputs Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity under the Equity Plans Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to determine grant-date fair value of stock options Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense related to issuance of stock option awards recognized in condensed consolidated statements of operations and comprehensive loss Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share No definition available Liquidity [Abstract] Liquidity Represents the expected research and development tax incentive payments from the Commonwealth of Australia. Research And Development Expected Incentive Payments Expected Research and development tax incentive payments Minimum period for Research and Development tax incentive to fund operating expense, 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Minimum Period Of Operating Expense Funding Minimum period to fund Operating expense No definition available. Research And Development Incentive Income And Receivable [Abstract] Research and development incentive income and receivable Percent of total eligible research and development expenses incurred by the Company that are reimbursed through the Australian Government research and development incentive related to the Australian Income Tax Assessment Act 1997. Australian Research And Development Incentive Percent Expenses Reimbursed Research and development expenses reimbursed (as a percent) No definition available. Research And Development Incentive Income And Receivable [Roll Forward] Research and development incentive income and receivable Carrying amount as of the balance sheet date of research and development incentive receivable within one year or during the operating cycle, if shorter. Research and Development Incentive Receivable Balance at the end of the period Balance at the beginning of the period The amount of cash received for the research and development incentive. Cash Received For Research And Development Incentive Cash received for 2016 eligible overseas research and development expenses The amount of foreign currency gain (loss) from research And Development incentive. Research And Development incentive, Foreign Currency Translation Gain (Loss) Foreign currency translation Amount of income related to overseas research and development activities performed during the year. Overseas Research And Development Incentive Income Overseas research and development incentive income Assets, Noncurrent [Abstract] Other Assets Deposits Assets, Noncurrent Deposits with service providers that are to be applied to future payments Security Deposit Deposit related to operating lease for office space in Cambridge, Massachusetts Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements Recurring [Member] Recurring Liability Class [Axis] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Fair Value by Liability Class [Domain] Warrant [Member] Warrant Liability Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level 1 Fair Value Inputs Level3 [Member] Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total assets Liabilities, Fair Value Disclosure [Abstract] Liabilities: Fair value of warrant liability. Warrant Liability, Fair Value Fair value of warrant liability Warrant liability Financial and Nonfinancial Liabilities, Fair Value Disclosure Total liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value measurements of the warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Ending Balance Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Loss (gain) on change in fair value Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition Acquiree [Domain] Business Acquisition Acquiree [Domain] Represents information pertaining to Macrocure Ltd, publicly held, clinical-stage Biotechnology company based In Petach Tikva, Israel, and M-Co Merger Sub Ltd, a wholly owned subsidiary of the company. Macrocure L T D [Member] Macrocure Business Acquisition [Line Items] Merger with Macrocure Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Common stock shares issued Business Acquisition, Percentage of Voting Interests Acquired Percentage of outstanding ordinary shares acquired Represents the approximate number of shares of stock of the reporting entity issued in exchange for each share of the acquiree upon consummation of the merger. Business Combination, Consideration Transferred, Equity Interests Issued, Conversion Ratio Approximate number of the Company's shares issued for each share of Macrocure's ordinary shares Share Price Common share value (in dollars per share) Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Final net cash calculation at closing Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Compensation cost related to the non-vested awards not yet recognized Compensation cost related to Macrocure equity awards, not yet recognized Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value One-time charge with the extension of the exercise periods Debt Conversion Description [Axis] Debt Conversion Name [Domain] Debt Conversion, Name [Domain] Conversion of related party notes payable and accrued interest into common stock. Conversion Of Related Party Notes Payable Into Common Stock [Member] Conversion of notes payable - related party and accrued interest into common stock Stock Conversion Description [Axis] Conversion Of Stock Name [Domain] Conversion of Stock, Name [Domain] Conversion of all outstanding shares of convertible preferred stock into common stock. Conversion Of Preferred Stock Into Common Stock [Member] Conversion of preferred stock into common stock Conversion of Stock, Shares Issued Shares issued on conversion of preferred stock Debt Conversion, Converted Instrument, Shares Issued Shares issued on conversion of notes payable and related accrued interest Preferred Stock, Shares Authorized Preferred Stock, shares authorized Stockholders' Equity Note, Stock Split, Conversion Ratio Stock split ratio Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Repurchase Agreement Counterparty Name [Domain] Represents information pertaining to a subscription agreement between the Company and HealthCare Ventures IX, L.P. ("HCV IX"). Health Care Ventures [Member] HCV IX Shares Issued, Price Per Share Price per share (in dollars per share) Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Represent information pertaining to 2012 equity incentive plan. Equity Incentive Plan2012 [Member] 2012 Plan Vesting [Axis] Vesting [Domain] Vesting [Domain] Share Based Compensation Award Tranche One [Member] Vesting on first anniversary Represents the number of executives to whom the Company granted options to purchase shares of common stock in connection with a merger agreement. Business Combination, Share-Based Compensation, Options, Grants in Period,, Number Of Executives Number of executives Represents the number of shares of common stock each executive can purchase with options granted in connection with a merger agreement. Business Combination, Share-Based Compensation, Options, Grants in Period,, Number Of Shares Per Executive Number of shares which can be purchased by each executive Represents the aggregate number of shares of common stock which can purchase with options granted to executives in connection with a merger agreement. Business Combination, Share-Based Compensation, Options, Grants in Period, Aggregate Number Of Shares Aggregate number of shares which can be purchased by executives Represents the exercise price per share of options to purchase common stock granted to executives in connection with a merger agreement. Business Combination, Share-Based Compensation, Options, Grants in Period, Exercise Price Per Share Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Options vesting on the first anniversary date of the grants (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Represents the remaining vesting period subsequent to the first anniversary of the date of the grant. Share-Based Compensation Arrangement By Share-Based Payment Award, Remaining Award Vesting Period Vesting period subsequent to the first anniversary of the grant date Products and Services [Axis] Products And Services [Domain] Products and Services [Domain] Represents information pertaining to sales of the Company's product TRX 518 compound. T R X518 Compound [Member] TRX 518 compound Represents information pertaining to sales of the Company's product DKN-01 compound. D K N01 Compound [Member] DKN-01 compound Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents information pertaining to the royalty agreement between the Company and Leap Shareholder Royalty Vehicle, LLC. Royalty Agreement [Member] Royalty Agreement Represents information pertaining to Leap Shareholder Royalty Vehicle, LLC, a Delaware limited liability company (the "Royalty Vehicle"), a special purpose vehicle formed for the specific purpose of entering into a royalty agreement with the Company. Leap Shareholder Royalty Vehicle Llc [Member] Royalty Vehicle Limited Liability Company (LLC) or Limited Partnership (LP), Members or Limited Partners, Ownership Interest Collective beneficial ownership (as a percent) Represents the portion of revenues of a specified product line payable to a special purpose entity pursuant to a royalty agreement. Revenue Sharing Agreement, Percentage Royalties payable Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Clinical Trials, Current Clinical trials Accrued Professional Fees, Current Professional fees Employee-related Liabilities, Current Payroll and related expenses Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short Term Debt Type [Domain] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Convertible Promissory notes Debt Instrument [Axis] Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Information pertaining to any convertible promissory note executed with stockholder. Promissory Convertible Note Executed With Stockholder [Member] Convertible promissory note executed with stockholder Related Party [Axis] Related Party [Domain] Related Party [Domain] Investor [Member] Stockholder Short-term Debt [Line Items] Proceeds from promissory notes Debt Instrument, Interest Rate, Stated Percentage Note interest rate (as a percent) Notes Payable, Related Parties Promissory notes payable outstanding Interest Payable Accrued interest expense Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Equity [Member] Equity Liability [Member] Liability Represents information pertaining to warrants expires on 11/14/2024. Warrants Expires On2024 [Member] Warrants expires on 2024 Class of Warrant or Right [Line Items] Warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of Shares Issuable Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrant Represents the number of votes that each common share is entitled to. Number of Vote on Common Shares Number of votes each common share is entitled to Dividends, Common Stock Dividend declared Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Range [Axis] Range [Member] Range [Member] Minimum [Member] Minimum Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Expense [Member] Other expense Represents information pertaining to HealthCare Ventures IX, L.P. and Eli Lilly and Company. Health Care Ventures Ix L.p. And Eli Lilly And Company [Member] HCV IX and Eli Lilly Subsidiary, Sale of Stock [Line Items] Private Placement of Common Stock Proceeds from Issuance of Private Placement Gross proceeds Number of warrants issued on purchase of one common stock. Number of warrants issued on purchase of one common stock Number of warrants issued per common stock The period of exercise of warrants expiration. Exercise Expiring Period Exercise expiring period The cash inflow associated with the amount received from entity's raising of capital via public placement after allocating to fair value of warrants. Proceeds from Issuance of Private Placement After Allocation to Fair Value of Warrants Remaining proceeds allocated to common stock The cash inflow associated with the amount received from entity's raising of capital via public placement after deducting issuance costs. Proceeds from Issuance of Private Placement, Net of Issuance Costs Net proceeds from issuance of stock in private placement The estimated cash inflow associated with the amount received from holders if all of the warrants are exercised during the term. Expected Proceeds from Exercise of Warrants Additional proceeds from exercise of warrants Estimated number of common shares issuable if all of the warrants are exercised during the term. Expected Issue of Common Stock on Exercise of Warrants, Shares Additional shares issuable on exercise in cash of warrants Percentage of allocation of issuance costs to warrants. Percentage of Allocation of Issuance Costs to Warrants Allocation of issuance cost to warrants (as a percentage) Percentage of allocation of issuance costs to common stock. Percentage of Allocation of Issuance Costs to Common Stock Allocation of issuance cost to common stock (as a percentage) The issuance cost allocated to warrants. Issuance Cost for Warrants Issuance costs associated with warrants The percentage of direct holding of company's common stock. Direct Holding Common Stock Percentage Direct holding percentage Number of company's directors and executive officers are affiliated . Number of Affiliated Directors and Executive Officers Number of affiliated directors and executive officers Number of days to register for resale the shares and the warrant Shares with SEC. Number of Days to Register for Resale Shares and Warrant Shares Number of days for registration Number of days SEC to declare the registration statement effective. Number of Days to Declare Registration Statement Number of days for declaration Number of days to registration statement is selected for review by SEC. Number of Days to Registration Statement Selected for Review Number of days for review Number of Purchasers opted not to register their Shares or Warrant Shares and therefore, such were not included in the Registration Statement. Number of Purchasers Opted Not to Register Shares or Warrant Shares Number of purchasers not registered Sale of stock by company to public. Public Offering [Member] Pub Over Allotment Option [Member] Over-Allotment Option Shares, Issued Shares issued Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Represents information pertaining to out-of-the-money options issued by Macrocure prior to the closing of the merger and assumed by the Company pursuant to the merger agreement. Business Acquisition Stock Options Assumed [Member] Out-of-the-money options Represent information pertaining to equity incentive plan 2012 amended in January 2017. Equity Incentive Plan2012 Amended In January2017 [Member] 2012 Plan amended in January 2017 Represents information pertaining to the 2016 Equity Incentive Plan. Equity Incentive Plan2016 [Member] 2016 Plan Maximum [Member] Maximum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-Based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Number of options issued under the plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares issuable Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional shares issuable Represents the annual increase in shares authorized for issuance, effective January 1, 2018, as a percent. Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized, Annual Increase, Percentage Annual increase in authorized shares (as a percent) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Research And Development Expense [Member] Research and development General And Administrative Expense [Member] General and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense included in the unaudited condensed consolidated statements of operations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding balance at the end of the period (in shares) Outstanding balance at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options vested and expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding balance at the end of the period (in dollars per share) Outstanding balance at the beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options vested and expected to vest at end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Life in Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options exercisable at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options vested and expected to vest at end of the period No definition available Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Options vested and expected to vest at end of the period Allocated Share-based Compensation Expense Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to determine grant-date fair value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percentage) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Expiration period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average period for recognition of compensation cost Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Numerator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Denominator: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities Name [Domain] Employee Stock Option [Member] Stock Options This member stands for warrants assumed from merger with Macrocure. Warrants Assumed From Merger With Macrocure [Member] Warrants assumed from Macrocure This member stands for warrants issued under private placement. Warrants Under Private Placement [Member] Warrants issued with the Private Placement Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from calculation of diluted net loss per share Schedule of Operating Leased Assets [Table] Lease Arrangement, Type [Axis] Lease Arrangement Type [Domain] Lease Arrangement, Type [Domain] Represents information pertaining to the assignment agreement to assume an operating lease for the Company's office space in Cambridge, MA. Covers the 12 month period ending July 31, 2017. Operating Lease Period One [Member] Operating lease - 12 month period ending July 31, 2017 Represents information pertaining to the assignment agreement to assume an operating lease for the Company's office space in Cambridge, MA. Covers the 12 month period ending July 31, 2018. Operating Lease Period Two [Member] Operating lease - 12 month period ending July 31, 2018 Represents information pertaining to the assignment agreement to assume an operating lease for the Company's office space in Cambridge, MA. Covers the period ending April 30, 2019. Operating Lease Period Three [Member] Operating lease - period ending April 30, 2019 Operating Leased Assets [Line Items] Commitments and Contingencies Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Annual rent Other Commitments [Table] Indefinite-lived Intangible Assets [Axis] Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Represents information pertaining to license and service agreements. License And Service Agreements [Member] License and service agreements Licensing Agreements [Member] Licensing agreements Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Preferred Class A [Member] Preferred Class A Represent information pertaining to TRX518 and DKN-01 product. T R X518 And D K N01 [Member] TRX518 and DKN-01 Other Commitments [Line Items] Commitments and Contingencies Supply Commitment, Remaining Minimum Amount Committed Noncancelable commitments Stock Issued During Period, Shares, Issued for Services Issuance of stock in consideration for license (in shares) Accrued Royalties Accrued royalties Loss Contingencies [Table] Represents information pertaining to the TRX518 product. T R X518 [Member] TRX518 Represent information pertaining to the TRX518 product in combination with a chemotherapeutic agent. T R X518 And Chemotherapeutic [Member] TRX518 and Chemotherapeutic Loss Contingencies [Line Items] Loss Contingencies Represents the number of notices of opposition filed against a patent granted to the entity. Loss Contingency Number Of Notices Of Opposition Filed Number of notices of opposition filed Represents the number of major pharmaceutical companies that filed notices of opposition to a patent granted to the entity. Number Of Major Pharmaceutical Companies Filed Notices Of Opposition Number of major companies that filed notices of opposition Represents the number of individuals that filed notices of opposition to a patent granted to the entity. Number Of Individual Possibly On Behalf Of A Major Pharmaceutical Company Filed Notices Of Opposition Number of individuals that filed notices of opposition Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Transactions